Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$20.83
-2.8%
$22.17
$19.10
$29.55
$1.02B1.79420,336 shs408,131 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$4.20
+1.7%
$3.25
$1.60
$16.55
$306.56M1.181.09 million shs924,507 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.11
$4.65
$13.13
$1.10B1.471.18 million shs19.38 million shs
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$15.10
-3.5%
$16.20
$13.50
$25.00
$1.05B1.56173,990 shs210,216 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-2.75%-5.10%-3.21%-4.93%-7.46%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
+1.69%+5.53%+21.74%+116.49%-64.88%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.08%+54.00%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-3.51%-5.80%+0.33%-14.88%-7.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.3967 of 5 stars
3.51.00.00.02.52.50.6
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
2.3466 of 5 stars
4.61.00.00.02.00.80.0
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
3.7979 of 5 stars
3.50.00.04.21.64.20.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$31.1749.62% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56198.94% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
3.00
Buy$22.0045.70% Upside

Current Analyst Ratings Breakdown

Latest CATX, FNA, PLSE, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/12/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
5/14/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
5/13/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/13/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M12.11$0.12 per share174.84$7.52 per share2.77
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
$700K1,451.11N/AN/A$1.87 per share8.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.29N/AN/AN/A-11.81%-0.66%-0.58%8/14/2025 (Estimated)
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$53.58MN/A0.00N/AN/A-68.44%-58.17%8/14/2025 (Estimated)

Latest CATX, FNA, PLSE, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.02N/AN/AN/AN/AN/A
8/14/2025Q2 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
-$0.26N/AN/AN/AN/AN/A
8/13/2025N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$0.30N/AN/AN/A$0.17 millionN/A
5/8/2025Q1 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.03$0.04+$0.07-$0.01$22.22 million$23.94 million
5/8/2025Q1 2025
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A-$0.25N/A-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.01
4.73
3.74
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
N/A
15.58
15.58

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
76.95%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.52%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
71.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.83 million46.78 millionOptionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.23 million65.21 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
14067.27 million19.17 millionOptionable

Recent News About These Companies

Pulse Biosciences: Some Key Questions Remain Unanswered

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$20.83 -0.59 (-2.75%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$20.82 0.00 (-0.02%)
As of 07/18/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$4.20 +0.07 (+1.69%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.22 +0.02 (+0.48%)
As of 07/18/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Pulse Biosciences stock logo

Pulse Biosciences NASDAQ:PLSE

$15.10 -0.55 (-3.51%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$15.12 +0.02 (+0.13%)
As of 07/18/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.